Treatment of Chronic Pain in Older PeopleEvidence-Based Choice of Strong-Acting Opioids

被引：0
作者：
Annette L. van Ojik
Paul A. F. Jansen
Jacobus R. B. J. Brouwers
Eric N. van Roon
机构：
[1] University Medical Center,Expertise Centre for Pharmacotherapy in Old Persons (Ephor)
[2] Medical Centre Leeuwarden,Department of Clinical Pharmacy & Pharmacology
[3] University Medical Centre,Department of Geriatrics
[4] University of Groningen,Department of Pharmacotherapeutics and Pharmaceutical Care
来源：
Drugs & Aging | 2012年 / 29卷 / 8期
关键词：
Morphine; Fentanyl; Buprenorphine; Oxycodone; Hydromorphone;
D O I：
10.1007/BF03262278
中图分类号：
学科分类号：
摘要：
In the treatment of chronic malignant and non-malignant pain, opioids are used as strong analgesics. Frail elderly patients often have multiple comorbidities and use multiple medicines, leading to an increased risk of clinically relevant drug-drug and drug-disease interactions. Age-related changes and increased frailty may lead to a less predictable drug response, increased drug sensitivity, and potential harmful drug effects. As a result, physicians face a complex task in prescribing medication to elderly patients. In this review, the appropriateness of the strong-acting opioids buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone and tapentadol is determined for use in elderly patients. Evidence-based recommendations for prescribing strong opioids to the frail elderly are presented.
引用
收藏
页码：615 / 625
页数：10
相关论文
共 117 条
[11]  
Scarpace P.J.(2011)Transdermal buprenorphine for the treatment of chronic noncancer pain in the oldest old J Pain Symptom Manage 41 707-14
[12]  
Lowenthal D.T.(2003)Transdermal fentanyl for the management of cancer pain: a survey of 1,664 elderly patients [abstract] Zhongua Yi Xue Za Zhi 83 1931-5
[13]  
Turnheim K.(2011)Post hoc analyses of data from a 90-day clinical trial evaluating the tolerability and efficacy of tapentadol immediate release and oxycodone immediate release for the relief of moderate to severe pain in elderly and nonelderly patients Pain Res Manage 16 245-51
[14]  
Bowie M.W.(2009)Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study Curr Med Res Opin 25 1095-104
[15]  
Slattum P.W.(2005)Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomised trials of oral opioids Arthritis Res Ther 7 R1046-50
[16]  
Hammerlein A.(2003)Management of opioid side effects in cancer-related and chronic noncancer pain: a systematic review J Pain 4 231-56
[17]  
Derendorf H.(2003)Responsible prescribing of opioids for the management of chronic pain Drugs 63 17-32
[18]  
Lowenthal D.T.(2004)Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain Cur Med Res Opin 20 1419-28
[19]  
Huisman-Baron M.(1997)Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life J Pain Symptom Manage 13 254-61
[20]  
van der Veen L.(2011)Tapentadol in pain management, a μ-opioid receptor agonist and noradrenaline reuptake inhibitor CNS Drugs 25 359-70
12345678910